SBS:XETRA-Stratec SE (EUR)

COMMON STOCK | Medical Devices | XETRA

Last Closing Price

EUR 125.40

Change

0.00 (0.00)%

Market Cap

EUR 1.56B

Volume

8.36K

Avg Analyst Target

EUR 141.40 (+12.76%)

Avg User Target

EUR
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Stratec SE (SBS) Stock Analysis:
Based on the Stratec SE stock forecasts from 3 analysts, the average analyst target price for Stratec SE is EUR 141.40 over the next 12 months. Stratec SE’s average analyst rating is . Stock Target Advisor’s own stock analysis of Stratec SE is Neutral, which is based on 6 positive signals and 7 negative signals. At the last closing, Stratec SE’s stock price was EUR 125.40. Stratec SE’s stock price has changed by -7.00 % over the past week, -14.40 % over the past month and +7.00 % over the last year.

About

Stratec SE designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment de ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-04 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABL:XETRA Abbott Laboratories

N/A

EUR200.56B 32.05 16.89
2M6:XETRA Medtronic plc

N/A

EUR131.34B 30.92 17.26
SYK:XETRA Stryker Corporation

N/A

EUR81.35B 49.97 25.00
PHI1:XETRA Koninklijke Philips N.V

N/A

EUR28.90B 7.32 27.59
EUZ:XETRA Eckert & Ziegler Strahlen- und..

N/A

EUR2.03B 55.00 33.85
DRW3:XETRA Drägerwerk AG & Co. KGaA

N/A

EUR1.10B 4.69 1.99
DRW8:XETRA Drägerwerk AG & Co. KGaA

N/A

EUR1.10B 4.40 1.99
MF6:XETRA MagForce AG

N/A

EUR0.10B 6.28 6.53
GME:XETRA Geratherm Medical AG

N/A

EUR0.05B 28.65 11.47
AAQ1:XETRA aap Implantate AG

N/A

EUR0.02B N/A N/A

ETFs Containing SBS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.12% 67% D+ 29% F
Dividend Return 0.73% 33% F 19% F
Total Return 2.85% 67% D+ 30% F
Trailing 12 Months  
Capital Gain 7.00% 58% F 37% F
Dividend Return 0.77% 33% F 20% F
Total Return 7.76% 58% F 38% F
Trailing 5 Years  
Capital Gain 195.13% 89% B+ 92% A-
Dividend Return 7.74% 43% F 35% F
Total Return 202.87% 89% B+ 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 27.32% 92% A- 91% A-
Dividend Return 0.97% 50% F 9% F
Total Return 28.29% 92% A- 91% A-
Risk Return Profile  
Volatility (Standard Deviation) 32.72% 42% F 22% F
Risk Adjusted Return 86.46% 92% A- 90% A-
Market Capitalization 1.56B 58% F 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.00 30% F 34% F
Price/Book Ratio 7.82 18% F 15% F
Price / Cash Flow Ratio 49.05 18% F 7% F
EV/EBITDA 22.00 40% F 21% F
Management Effectiveness  
Return on Equity 25.51% 73% C 77% C+
Return on Invested Capital 11.45% 67% D+ 76% C
Return on Assets 10.10% 100% A+ 89% B+
Debt to Equity Ratio 55.36% 36% F 46% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.28 58% F 94% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.